Cargando…

Hemodialysis and Peritoneal Dialysis in Germany from a Health Economic View—A Propensity Score Matched Analysis

Background: Hemodialysis (HD) and peritoneal dialysis (PD) are deemed medically equivalent for therapy of end-stage renal disease (ESRD) and reimbursed by the German statutory health insurance (SHI). However, although the home dialysis modality PD is associated with higher patient autonomy than HD,...

Descripción completa

Detalles Bibliográficos
Autores principales: Shukri, Arim, Mettang, Thomas, Scheckel, Benjamin, Schellartz, Isabell, Simic, Dusan, Scholten, Nadine, Müller, Martin, Stock, Stephanie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9653857/
https://www.ncbi.nlm.nih.gov/pubmed/36360885
http://dx.doi.org/10.3390/ijerph192114007
_version_ 1784828784843685888
author Shukri, Arim
Mettang, Thomas
Scheckel, Benjamin
Schellartz, Isabell
Simic, Dusan
Scholten, Nadine
Müller, Martin
Stock, Stephanie
author_facet Shukri, Arim
Mettang, Thomas
Scheckel, Benjamin
Schellartz, Isabell
Simic, Dusan
Scholten, Nadine
Müller, Martin
Stock, Stephanie
author_sort Shukri, Arim
collection PubMed
description Background: Hemodialysis (HD) and peritoneal dialysis (PD) are deemed medically equivalent for therapy of end-stage renal disease (ESRD) and reimbursed by the German statutory health insurance (SHI). However, although the home dialysis modality PD is associated with higher patient autonomy than HD, for unknown reasons, PD uptake is low in Germany. Hence, we compared HD with PD regarding health economic outcomes, particularly costs, as potentially relevant factors for the predominance of HD. Methods: Claims data from two German health insurance funds were analysed in a retrospective cohort study regarding the prevalence of HD and PD in 2013–2016. Propensity score matching created comparable HD and PD groups (n = 436 each). Direct annual health care costs were compared. A sensitivity analysis included a comparison of different matching techniques and consideration of transportation costs. Additionally, hospitalisation and survival were investigated using Poisson regression and Kaplan-Meier curves. Results: Total direct annual average costs were higher for HD (€47,501) than for PD (€46,235), but not significantly (p = 0.557). The additional consideration of transportation costs revealed an annual cost advantage of €7000 for PD. HD and PD differed non-significantly in terms of hospitalisation and survival rates (p = 0.610/p = 0.207). Conclusions: PD has a slight non-significant cost advantage over HD, especially when considering transportation costs.
format Online
Article
Text
id pubmed-9653857
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96538572022-11-15 Hemodialysis and Peritoneal Dialysis in Germany from a Health Economic View—A Propensity Score Matched Analysis Shukri, Arim Mettang, Thomas Scheckel, Benjamin Schellartz, Isabell Simic, Dusan Scholten, Nadine Müller, Martin Stock, Stephanie Int J Environ Res Public Health Article Background: Hemodialysis (HD) and peritoneal dialysis (PD) are deemed medically equivalent for therapy of end-stage renal disease (ESRD) and reimbursed by the German statutory health insurance (SHI). However, although the home dialysis modality PD is associated with higher patient autonomy than HD, for unknown reasons, PD uptake is low in Germany. Hence, we compared HD with PD regarding health economic outcomes, particularly costs, as potentially relevant factors for the predominance of HD. Methods: Claims data from two German health insurance funds were analysed in a retrospective cohort study regarding the prevalence of HD and PD in 2013–2016. Propensity score matching created comparable HD and PD groups (n = 436 each). Direct annual health care costs were compared. A sensitivity analysis included a comparison of different matching techniques and consideration of transportation costs. Additionally, hospitalisation and survival were investigated using Poisson regression and Kaplan-Meier curves. Results: Total direct annual average costs were higher for HD (€47,501) than for PD (€46,235), but not significantly (p = 0.557). The additional consideration of transportation costs revealed an annual cost advantage of €7000 for PD. HD and PD differed non-significantly in terms of hospitalisation and survival rates (p = 0.610/p = 0.207). Conclusions: PD has a slight non-significant cost advantage over HD, especially when considering transportation costs. MDPI 2022-10-27 /pmc/articles/PMC9653857/ /pubmed/36360885 http://dx.doi.org/10.3390/ijerph192114007 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Shukri, Arim
Mettang, Thomas
Scheckel, Benjamin
Schellartz, Isabell
Simic, Dusan
Scholten, Nadine
Müller, Martin
Stock, Stephanie
Hemodialysis and Peritoneal Dialysis in Germany from a Health Economic View—A Propensity Score Matched Analysis
title Hemodialysis and Peritoneal Dialysis in Germany from a Health Economic View—A Propensity Score Matched Analysis
title_full Hemodialysis and Peritoneal Dialysis in Germany from a Health Economic View—A Propensity Score Matched Analysis
title_fullStr Hemodialysis and Peritoneal Dialysis in Germany from a Health Economic View—A Propensity Score Matched Analysis
title_full_unstemmed Hemodialysis and Peritoneal Dialysis in Germany from a Health Economic View—A Propensity Score Matched Analysis
title_short Hemodialysis and Peritoneal Dialysis in Germany from a Health Economic View—A Propensity Score Matched Analysis
title_sort hemodialysis and peritoneal dialysis in germany from a health economic view—a propensity score matched analysis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9653857/
https://www.ncbi.nlm.nih.gov/pubmed/36360885
http://dx.doi.org/10.3390/ijerph192114007
work_keys_str_mv AT shukriarim hemodialysisandperitonealdialysisingermanyfromahealtheconomicviewapropensityscorematchedanalysis
AT mettangthomas hemodialysisandperitonealdialysisingermanyfromahealtheconomicviewapropensityscorematchedanalysis
AT scheckelbenjamin hemodialysisandperitonealdialysisingermanyfromahealtheconomicviewapropensityscorematchedanalysis
AT schellartzisabell hemodialysisandperitonealdialysisingermanyfromahealtheconomicviewapropensityscorematchedanalysis
AT simicdusan hemodialysisandperitonealdialysisingermanyfromahealtheconomicviewapropensityscorematchedanalysis
AT scholtennadine hemodialysisandperitonealdialysisingermanyfromahealtheconomicviewapropensityscorematchedanalysis
AT mullermartin hemodialysisandperitonealdialysisingermanyfromahealtheconomicviewapropensityscorematchedanalysis
AT stockstephanie hemodialysisandperitonealdialysisingermanyfromahealtheconomicviewapropensityscorematchedanalysis